Skip to main content
OpenTrials
Completed

NCT Number: NCT03262480

The Stroke Volume Optimization of Goal Directed Fluid Therapy During Radical Cystectomy

Although fluid therapy is of paramount value in anesthetic practice, there is no guideline available for perioperative fluid management in major abdominal surgery. So, there is a need to establish whether goal directed fluid therapy protocol is effective during radical cystectomy and urinary diversion. A balance of perioperative fluid therapy is crucial, yet the method to achieve this equilibrium remains a highly debated subject. Therefore, this study will be designed to investigate the effects of two individualized goal directed fluid therapy during radical cystectomy to encourage an effective circulating blood volume and pressure. Accordingly, as a primary outcome, the investigators assume that stroke volume optimization could maintain better perioperative hemodynamic stability with low incidence and severity of hypotensive episodes together with achievement of maximal oxygenation. Hopefully this regimen could help to decrease the possibility of perioperative tissue hypoperfusion and the possible associated complications as a secondary outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Radical Cystectomy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Urology and nephrology center

Al Mansurah, Dakahlia Governorate, +2050, Egypt

About this study

Study protocol:

Patients will be randomly assigned to one of two equal groups, according to computer-generated randomization sequence into:

  • Stroke volume optimization group (SVO group).
  • Central venous pressure dynamic group(CVPdyngroup).

Stroke volume optimization group (SVO group):

Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven, Fresenius kabi, Deutschland GmbH, Bad Homburg, Germany) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated. No further aliquots will be given once stroke volume failed to increase >10%. The last stroke volume without rise of > 10% will be defined as optimum stroke volume (SVopt).When stroke volume decreases by 10% below (SVopt), this will be defined as trigger stroke volume (SVT). Stroke volume will be followed every 30 minutes during surgery and every 4 hours for 24 hours postoperatively .

Central venous pressure dynamic group (CVPdyn group):

Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated. No further aliquots will be given once CVP increases more than 2 mmHg above the recorded one.The last CVP with sustained rise of>2 mmHg will be defined as CVP maximum (CVPmax).When CVP decrease below (CVPmax)by 3 mmHg, this will be defined as trigger CVP (CVPT).CVP will be followed every 30 min during surgery and every 4 hours for 24 hours postoperatively

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with American Society of Anesthesiologists (ASA) physical status I - II scheduled for radical cystectomy and urinary diversion for muscle invasive urinary bladder carcinoma .
  • Both sexes

Exclusion criteria

  • Patients younger than 18 years
  • Body mass index (BMI) < 25 and >35.
  • Patients with any contraindications to epidural anesthesia (patient refusal, local skin infection, previous spine surgery and coagulopathy).
  • Those with known allergy to local anesthetics.
  • Patients with major cardiovascular problems with ejection fraction < 40 .
  • Renal impairment with serum creatinine >1.8 mg/dl
  • Patients with hepatic dysfunction will be excluded.

Treatment and study plan

stroke volume optimization

Other

Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.

If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.

Other names: central venous pressure dynamic

Primary outcomes

  1. Perioperative hypotension

    Time frame: perioperative

    Mean arterial blood pressure < 65mmHg

  2. Maximal tissue oxygenation

    Time frame: perioperative

    Oxygen delivery index > 550 ml/min/m2

Secondary outcomes

  1. Medical postoperative complication

    Time frame: 48 hours postoperative

    Acute kidney injury (AKI) . Postoperative serum creatinine value is either more than 1.5-fold or more than 0.3 mg/dl before surgery within 48 hours

  2. Surgical postoperative complication

    Time frame: 7-days postoperative

    Nausea, vomiting, abdominal distension, anastomotic leakage, paralytic ileus

  3. Anesthetic postoperative complication

    Time frame: 24 hours postoperative

    Cardiogenic pulmonary edema.Cardiac index < 2.5 l/min/m2

  4. Surgical postoperative complication

    Time frame: 7-days postoperative

    Wound infection and burst abdomen

  5. Respiratory postoperative complication

    Time frame: 7-days postoperative

    Pneumonia, acute respiratory distress, postoperative ventilation and ICU admission.length of ICU stay in days.

  6. Postoperative complication

    Time frame: 7-days postoperative

    mortality

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Official study title

Perioperative Goal Directed Fluid Therapy During Radical Cystectomy: the Impact of Stroke Volume Optimization vs Dynamic Central Venous Pressure

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Aug 25, 2017
Registry last updated
Dec 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.